| Scorecard |
|---|
|
5 / 5 Stars
|
|
Lipper
5
5
4
5
4
|
|
Zacks Investment Research
1
(Strong Buy)
|
|
Standard & Poor's
5 / 5 Stars
|
|
TheStreet.com
A
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 0.43 | 0.43 |
| Stocks | 98.1 | 98.1 |
| Bonds | 0.0 | 0.0 |
| Other | 0.0 | 0.0 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 1.45 | 1.45 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.02 | 0.02 |
Updated 04.30.2013
Top 10 Holdings
Performance as of 05.31.2013
Portfolio as of 04.30.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Amgen Inc | AMGN | 16.09 | 15.01 |
| Gilead Sciences Inc | GILD | 44.64 | 14.43 |
| Celgene Corporation | CELG | 54.06 | 7.4 |
| Biogen Idec Inc | BIIB | 55.35 | 6.95 |
| Vertex Pharmaceuticals | VRTX | 89.33 | 4.7 |
| Alexion Pharmaceuticals, Inc. | ALXN | 1.86 | 4.51 |
| Regeneron Pharmaceuticals, Inc. | REGN | 38.0 | 4.16 |
| Biomarin Pharmaceutical, Inc. | BMRN | 21.5 | 2.78 |
| Onyx Pharmaceuticals, Inc. | ONXX | 23.34 | 2.47 |
| Medivation, Inc. | MDVN | -4.79 | 2.0 |
